📰 Segmentation By Indication News
Page 3 - Segmentation By Indication News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Segmentation By Indication. Real-time updates on events, politics, business and more.
June 22, 2022
/PRNewswire/ -- The "Antisense & RNAi Therapeutics Global Market Report 2022: By Technology, By Route, By Indication" report has been added to...
June 2, 2022
The dementia drugs market is expected to expand due to the rising prevalence of dementia and neurological disorders, such as vascular dementia, along with...
April 4, 2022
/PRNewswire/ -- The "Alpha Mannosidosis Global Market Opportunities And Strategies To 2030, By Therapy Type, Indication, End-User" report has been added to...
May 11, 2021
Share this article Share this article ResearchAndMarkets.coms offering. Major players in the trastuzumab biosimilar market are Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries Ltd. and EirGenix, Inc. The global trastuzumab biosimilars market is expected to decline from $1.27 billion in 2019 to $1.25 billion in 2020 at a compound annual growth rate (CAGR) of -1.50%. The decline is mainly due to th...
December 17, 2020
Share this article Share this article ResearchAndMarkets.coms offering. Antisense & RNAi Therapeutics Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global antisense & RNAi therapeutics market. Major players in the antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosci...